ProShare Advisors’s Cidara Therapeutics CDTX Stock Holding History

ProShare Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,002	Closed	-$1.1M	–	1898
2025 Q4	$1.1M	Buy	5,002 +2,357	+89%	+$381K	﹤0.01%	794
2025 Q3	$253K	Buy	+2,645	New	+$169K	﹤0.01%	1553

ProShare Advisors's CDTX Position: Q1 2026 in Review

ProShare Advisors sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 5,002 shares — an estimated $1.1M sold.

ProShare Advisors first reported a position in CDTX in Q3 2025 and held it in 2 quarters. The position peaked at $1.1M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

ProShare Advisors reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
ProShare Advisors sold 5,002 Cidara Therapeutics shares in Q1 2026, an estimated $1.1M.
ProShare Advisors first reported a position in Cidara Therapeutics in Q3 2025 and held it in 2 quarters.
ProShare Advisors's Cidara Therapeutics position peaked at $1.1M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.